May 25, 2023 | Troy, VA
The BIO-CAT R&D team has recently published a new preclinical study focused on inulinase-mediated FODMAP digestion in the prestigious scientific journal Frontiers in Nutrition. The data supports the potential for inulinase enzyme supplementation across physiologically relevant gastric conditions, thus setting the stage for a clinical efficacy trial. BIO-CAT has initiated a clinical trial designed to determine the safety and tolerability of high-dose microbial inulinase supplementation. The upcoming clinical trial has received approval via Health Canada, and will be managed by Nutrasource. Read the press release here.
BIO-CAT is committed to providing the highest quality enzymes to support the health and wellbeing of its customers. The publication of this preclinical study is a testament to BIO-CAT’s commitment to research and innovation.
